Pharsight

Zilretta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555048 PACIRA PHARMS INC Corticosteroids for the treatment of joint pain
Aug, 2031

(7 years from now)

US8828440 PACIRA PHARMS INC Corticosteroids for the treatment of joint pain
Aug, 2031

(7 years from now)

Zilretta is owned by Pacira Pharms Inc.

Zilretta contains Triamcinolone Acetonide.

Zilretta has a total of 2 drug patents out of which 0 drug patents have expired.

Zilretta was authorised for market use on 06 October, 2017.

Zilretta is available in for suspension, extended release;intra-articular dosage forms.

Zilretta can be used as method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide.

The generics of Zilretta are possible to be released after 04 August, 2031.

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 06 October, 2017

Treatment: Method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

More Information on Dosage

ZILRETTA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic